Zalicus Regains Compliance with Nasdaq Listing Requirements

  Zalicus Regains Compliance with Nasdaq Listing Requirements

Business Wire

CAMBRIDGE, Mass. -- October 15, 2013

Zalicus Inc. (the “Company”) today announced that it has received notice from
the Listing Qualifications Staff of The Nasdaq Stock Market LLC that the
Company has regained compliance with Nasdaq Marketplace Rule 5550(a)(2)
relating to the maintenance of a minimum $1.00 bid price. The matter is now
closed.

About Zalicus

Zalicus Inc. (Nasdaq Capital Market: ZLCS) is a biopharmaceutical company that
discovers and develops novel treatments for patients suffering from pain.
Zalicus has a portfolio of proprietary clinical-stage product candidates
targeting pain such as Z160 and Z944 and has entered into multiple
revenue-generating collaborations with large pharmaceutical companies relating
to other products, product candidates and drug discovery technologies. Zalicus
applies its expertise in the discovery and development of selective ion
channel modulators and its combination high throughput screening capabilities
to discover innovative therapeutics for itself and its collaborators in the
areas of pain, inflammation, oncology and infectious disease. To learn more
about Zalicus, please visit www.zalicus.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995 concerning Zalicus, its
potential and its other business plans. These forward-looking statements about
future expectations, plans, objectives and prospects of Zalicus and its
product candidates may be identified by words like "believe," "expect," "may,"
"will," "should," "seek," “plan” or “could” and similar expressions and
involve significant risks, uncertainties and assumptions, including risks
related to the unproven nature of the Zalicus drug discovery technologies, the
Company's ability to obtain additional financing or funding for its research
and development, and those other risks that can be found in the "Risk Factors"
section of Zalicus' annual report on Form 10-K on file with the Securities and
Exchange Commission and the other reports that Zalicus periodically files with
the Securities and Exchange Commission. Actual results may differ materially
from those Zalicus contemplated by these forward-looking statements. These
forward-looking statements reflect management’s current views and Zalicus does
not undertake to update any of these forward-looking statements to reflect a
change in its views or events or circumstances that occur after the date of
this release except as required by law.

(c) 2013 Zalicus Inc. All rights reserved.

Contact:

Zalicus Inc.
Justin Renz, 617-301-7575
CFO
JRenz@zalicus.com
or
Gina Nugent, 617-460-3579
gnugent@zalicus.com
 
Press spacebar to pause and continue. Press esc to stop.